Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
AIDX Stock — 20/20 Biolabs, Inc. Common Stock
20/20 Biolabs, Inc. Common Stock (AIDX)
Updated November 13, 2026.
AIDX is a stock. Total return is -99.1% over the past 0.7 years, 110.2 points behind SPY at 11.1%.
20/20 Biolabs, Inc. develops AI-powered blood tests for early detection of cancers and chronic diseases, offering products including OneTest for Cancer, a multi-cancer early detection test, and OneTest for Longevity, which measures inflammatory biomarkers; the company also operates CLIAx, a clinical laboratory serving overseas diagnostics startups. The company does not currently distribute to shareholders. This stock appeals to investors seeking exposure to healthcare innovation and early-stage diagnostic technology companies, rather than those focused on income generation.
AIDX performance versus SPY
Total return is -99.1% over the past 0.7 years, 110.2 points behind SPY at 11.1%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | -41.6% | — |
| 3M | -60.7% | — |
| 6M | -85.4% | — |
| YTD | -99.1% | — |
| Since inception 2026-02-19 · 0.7 years | -99.1% | — |
AIDX key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 02/19/2026
- Distribution frequency
- None
- Last close
- $0.20 (as of 2026-11-13)
- Market cap
- $2,730,920
- Average volume
- 52,928
- Beta
- -0.425
- Payout ratio
- 0.0%
- EPS
- -$0.75
How Dividend Vision calculates returns
Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
AIDX risks and drawbacks
Total return has trailed SPY over the available window.
Who may consider AIDX — and who may not
It is a weaker fit for investors who need monthly cash flow (AIDX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on AIDX
Frequently asked questions
Does AIDX pay monthly?
No. AIDX does not currently distribute.
When does AIDX pay a dividend?
AIDX does not currently distribute.
How has AIDX performed?
Total return is -99.1% over the past 0.7 years, 110.2 points behind SPY at 11.1%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.